I think he may be intimating that WP, while compensated well as...

I think he may be intimating that WP, while compensated well as CEO, has incurred opportunity costs e.g. better paying jobs at Merck or wherever and without the significant hassle of small shareholders hassling at all times of the day and night. And remember they were in discussions with 4C Medical for 6-7 months and an unknown amount of time in negotiations with the unknown prospective investor in Immunotherapies so its safe to say none of management would be able to buy shares if they wanted to this year.

In relation to ADAPT sales trends, I think I will defer to how many years it took Lemaitre Vascular to gain traction (see below).... also, WP has put his a-s-s on the line and given us detailed sales guidance for 2018. I think we therefore need to be patient and have this conversation same time next year...